farxiga
AstraZeneca’s Farxiga approved to reduce risk of cardiovascular death
May 9, 2023Medical Communications AstraZeneca, Cardiology, FDA, cvd, farxiga, heart failure
AstraZeneca has announced that the US Food and Drug Administration (FDA) has approved Farxiga to reduce the risk of cardiovascular …
AstraZeneca’s Farxiga falls short in Phase III trials for treatment of COVID-19
April 13, 2021Manufacturing and Production AstraZeneca, COVID-19, covid-19 treatment, farxiga, pharma, pharma news
AstraZeneca’s Farxiga drug, usually used in patients with diabetes, did not show statistical significance in the Phase III trial into …
AstraZeneca’s Farxiga granted Priority Review by FDA
January 6, 2021Research and Development AstraZeneca, FDA, farxiga
AstraZeneca’s Farxiga (dapagliflozin) has been granted Priority Review in the US for the treatment of new or worsening chronic kidney …
Farxiga smashes all goals in Phase 3 chronic kidney disease trial, says AstraZeneca
July 28, 2020Manufacturing and Production, Research and Development AstraZeneca, farxiga
AstraZeneca has teased new data from a Phase 3 study of its sodium-glucose co-transporter-2 (SGLT2) inhibitor Farxiga (dapagliflozin) in the …
AstraZeneca secures accelerated FDA review for Farxiga for for CV death following heart attacks
July 17, 2020Medical Communications, Research and Development, Sales and Marketing AstraZeneca, FDA, farxiga, fast track
AstraZeneca has made it known that Farxiga (dapagliflozin) has secured Fast Track Designation from the FDA for the reduction of …
AZ’s Farxiga becomes first FDA-approved SGLT2 inhibitor for heart failure with reduced ejection fraction
May 6, 2020Research and Development, Sales and Marketing AstraZeneca, FDA, farxiga, heart failure
The FDA has moved to approve an oral tablet formulation of AstraZeneca’s Farxiga (dapagliflozin) to reduce the risk of cardiovascular …
FDA gives a priority review for key heart failure drug Farxiga
January 6, 2020Sales and Marketing AstraZeneca, Heart Failures, farxiga
The FDA has accepted a New Drug Application (sNDA) and has granted a priority review for AstraZeneca’s drug Farxiga (dapagliflozin) …
AstraZeneca’s Farxiga meets Phase 3 primary endpoint in heart failure
August 20, 2019Manufacturing and Production, Sales and Marketing AstraZeneca, cardiovascular disease, farxiga
New Phase 3 data has been unveiled for AstraZeneca’s Farxiga (dapagliflozin), confirming that the SGLT2 inhibitor met its primary composite …
AstraZeneca’s Farxiga fails to get FDA approval for patients with Type 1 diabetes
July 15, 2019Sales and Marketing AstraZeneca, EMA, FDA, US, diabetes, farxiga
The FDA had said it will not approve AstraZeneca’s diabetes drug Farxiga for use as a supplement to insulin in …
AstraZeneca’s Phase 3 Farxiga data impresses in type 2 diabetes
June 11, 2019Manufacturing and Production, Research and Development AstraZeneca, diabetes, farxiga, pharma, type 2 diabetes
AstraZeneca has presented new Phase 3 data at the American Diabetes Association (ADA) 79th Scientific Sessions in San Francisco on …
AZ’s Farxiga reduces major adverse cardiovascular event risk in type 2 diabetes, new data shows
March 19, 2019Manufacturing and Production, Research and Development AstraZeneca, cardiovascular, farxiga, pharma
AstraZeneca has lifted the curtain on new Phase 3 data for its sodium-glucose co-transporter 2 (SGLT2) inhibitor Farxiga (dapagliflozin), reinforcing …
AZ’s Farxiga shows strength in largest ever SGLT2 inhibitor cardiovascular outcomes study
November 12, 2018Research and Development, Sales and Marketing AstraZeneca, cardiovascular, farxiga, pharma
AstraZeneca has revealed new data for its sodium-glucose co-transporter 2 (SGLT2) inhibitor Farxiga (dapagliflozin) at the American Heart Association (AHA) …
AstraZeneca’s Farxiga cuts heart risk in type 2 diabetes patients
September 24, 2018Research and Development, Sales and Marketing AstraZeneca, diabetes, farxiga, pharma
AstraZeneca has unveiled new Phase 3 data for its SGLT2 inhibitor Farxiga (dapagliflozin), showing with the drug demonstrating positive findings …
AstraZeneca’s Forxiga displays potential in type 1 diabetes
September 14, 2017Research and Development AstraZeneca, Forxiga, biotech, drugs, farxiga, pharma, pharmaceutical
Forxiga is AstraZeneca’s treatment for those living with type 2 diabetes but the results from a new trial have found …
FDA issues warnings on Janssen, AstraZeneca diabetes drugs
June 15, 2016Research and Development, Sales and Marketing AstraZeneca, FDA, Janssen, farxiga, invokana
The US Food and Drug Administration has issued a warning of the risk of acute kidney injury for the type-2 …
Latest content
Santen joins inaugural Global Summit for Eye Health as partner
